Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system,
with the potential to either stimulate or inhibit immune responses. Exploiting the immune-
regulatory capacities of dendritic cells holds great promise for the treatment of cancer,
autoimmune diseases and the prevention of transplant rejection. Although early clinical trials
indicate that DC vaccines can induce immune responses in some cancer patients, careful
study design and use of standardized clinical and immunological criteria are needed.